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Abstract
Background: Research ethics and the measures deployed to ensure ethical oversight of research (e.g., informed
consent forms, ethics review) are vested with extremely important ethical and practical goals. Accordingly, these
measures need to function effectively in real-world research and to follow high level standards.
Methods: We examined approved consent forms for Magnetic Resonance Imaging (MRI) and functional Magnetic
Resonance Imaging (fMRI) studies approved by Canadian research ethics boards (REBs).
Results: We found evidence of variability in consent forms in matters of physical and psychological risk reporting.
Approaches used to tackle the emerging issue of incidental findings exposed extensive variability between and
within research sites.
Conclusion: The causes of variability in approved consent forms and studies need to be better understood.
However, mounting evidence of administrative and practical hurdles within current ethics governance systems
combined with potential sub-optimal provision of information to and protection of research subjects support other
calls for more scrutiny of research ethics practices and applicable revisions.
Background
Research ethics and the measures deployed to ensure
ethical oversight of research (e.g., informed consent
forms, ethics review processes) are vested with extre-
mely important goals. [1] First and foremost, research
ethics aims to protect human subjects and inform them
of their rights and of the risks related to their participa-
tion in a research project. This has been a tenet of mod-
ern research ethics for decades and is consistent with
the inescapability of individual rights and respect for
autonomy in contemporary research. Second, as a result,
research ethics oversight makes it possible for research
to be carried on in contemporary social and political
environments where the failure to comply with basic
norms of ethics and individual rights can lead to severe
backlash on researchers, academic institutions, research
communities, and funding bodies. Hindered research
also translates into opportunity costs because the poten-
tial development of novel treatments and the beneficial
outcomes of research can be lost when unfortunate
research ethics events occur. [2,3] This is in addition to
precedent skids and their consequences that we still live
with. Therefore, all stakeholders in research have a
vested interest in attending diligently and seriously to
research ethics and human subject welfare in order to
ensure the continuity of the research enterprise and
to harness support for the deliverables of research.
To fulfill these important goals, the measures put in
place to deal with research ethics, issues such as
informed consent forms and ethics review need to work
effectively in real-world research and to follow high
level standards. [4] Fulfilling the goals of informing and
protecting subjects, as well as ensuring the continuity of
research, rely in large part on the ability of these mea-
sures to respond to current and future research ethics
challenges. Accordingly, many have called for further
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any medium, provided the original work is properly cited.evidence-based research ethics practices in the light of
apparent knowledge gaps and disquieting practical pro-
blems of ethics review. [5,6] In this paper, we report an
examination of consent forms approved by Canadian
Research Ethics Boards (REBs). We were interested in
comparing consent forms and understanding how they
met (or not) basic requirements of the established
Canadian Tri-Council Policy Statement (TCPS) as well
as how they dealt with emerging issues in neuroscience
research. As part of a broader study, we focused on neu-
roimaging research because Magnetic Resonance Ima-
ging (MRI) and functional Magnetic Resonance Imaging
(fMRI) research techniques often fit minimal risk criteria
[7] but have, nevertheless, sparked debates related to the
discovery of incidental findings [8,9] in research as well
as to the capabilities of neuroprediction of personality
and behaviour. [10,11]
Methods
Neuroimaging researchers participating to a broader
study on the challenges of ethics review in the Canadian
context were invited to submit their two most recently
approved informed consent forms in English or in
French. Consent forms for other techniques than MRI
and fMRI were excluded to focus the sample and analy-
sis (n = 23). Data was collected from 2008 to 2009.
Study Design
All forms were coded or parsed based on a standard
thematic qualitative content analysis approach. [12]
A coding guide was elaborated to support the analytic
process. This guide identified and defined the primary,
secondary and tertiary level codes and included exam-
ples for each code to guide coding. This guide was
drafted on the basis of the analysis of a diversified sam-
ple of consent forms where free nodes were generated
in an open-coding phase. The coding guide was devel-
oped to capture the content required for consent docu-
ments as described in the first edition of the TCPS. [13]
The TCPS constitutes the official research ethics policy
of the three major Canadian funding bodies: the Cana-
dian Institutes of Health Research (CIHR), the Natural
Science and Engineering Research Council of Canada
(NSERC), and the Social Sciences and Humanities
Research Council of Canada (SSHRC). All researchers
and institutions receiving funds from these bodies must
comply with the TCPS and, de facto, the TCPS has
become the “national” Canadian policy of reference even
though it has limited jurisdiction. Piloting and test cod-
ing were done on a small sub-sample of forms to ensure
validity and consistency. Ethical issues not explicitly
addressed in the TCPS but identified in the pilot sample
as featured in the consent forms were added to the cod-
ing guide. Specifications on how consent forms dealt
with TCPS requirements were also captured. Prelimin-
ary versions of the coding guide (drafted by WA) and of
the pilot coding were reviewed and discussed (by WA,
NP and ER) before final coding was conducted.
Data Analysis
All informed consent documents were then systemati-
cally coded (by NP and WA), i.e., the axial coding
phase, and a final review of the coding was conducted
by some of the investigators of the present study (by EB,
CD, and ER). The final coding guide included the fol-
lowing topics: (1) general conditions of informed con-
sent required by the current TCPS [13] (e.g., statement
of the research purpose, identity of the researcher; Sec-
tion D, Article 2.4, pages 2.5-2.6 of TCPS); (2) additional
items of informed consent that may be required by
REBs depending on the nature of the study (e.g., state-
ment that new information about the study will deliv-
ered to the subject in a timely manner, measures to
protection confidentiality) (Table 1, section D, page 2.7
of TCPS) and (3) a salient issue in the ethics of neuroi-
maging research: incidental findings. All coding was
supported by the use of the QSR NVivo 7 and 8 qualita-
tive analysis software packages (Doncaster, Australia).
REB approvals were obtained prior to the beginning of
this study for each targeted site. Results are reported
using descriptive statistics to quantify the presence of
coded items in consent forms. Qualitative data is used
to report salient aspects and strategies employed to deal
with ethical issues.
Results
We collected a total of 43 consent forms from 9 distinct
Canadian sites featuring research designs based on ana-
tomical MRI and functional MRI. Twenty-nine of the 41
(70.7%) researchers asked to submit their most recent
consent forms participated (submitted consent forms).
1. General conditions required for informed consent
The TCPS requires that (by default) some general con-
ditions be fulfilled in the written informed consent pro-
cess such as (1) specifying that the individual is invited
to a research project; (2) a statement of research pur-
pose, the identity of designated researcher, the expected
duration of study, and the description of research proce-
dures; (3) description of reasonably foreseeable harms
and benefits, and consequences of “non-action” (not
participating to the protocol); (4) assurance of freedom
not to participate, right to withdraw, identification of
continuing and meaningful opportunities to continue to
participate and (5) information on conflict of interest
and commercialization (see bold items in Table 1). [13]
In our sample, most of these items required by
t h eT C P Sw e r ei n c l u d e di na p p r o v e dc o n s e n tf o r m s
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forms included a sentence specifying that the consent
form was an invitation to research (e.g., “You are being
asked to participate in a research study” or “You have
been invited to take part in a research study”).
All forms included descriptions of research proce-
dures. Ninety one percent of informed consent forms
contained information describing the imaging device,
including 77% of forms describing physical aspects of
the device and 35% of forms describing operational
aspects. The TCPS requires that the expected duration
of the study be presented and this was present in all
consent forms. However, 98% stated the duration of
each visit; 91% the duration of patient participation; and
28% mentioned the total duration of the study. Specifi-
cations about the right of subjects to withdraw from the
study were encountered in all forms and the “conse-
quences of non-action” as defined by the TCPS were
found in most consent forms (e.g., “If you chose to stop
being in the study, this will not affect your ongoing
health care”, “Refusal to participate will involve no pen-
alty or loss of benefits to which you are otherwise
entitled” or “You are free to discontinue participation at
any time without prejudice to your subsequent care, and
are free to seek care from a health care provider of your
choice at any time”). Funding sources or sponsoring
partners of the protocols were identified in 23% of con-
sent forms. A general description of foreseeable risks
was present in all consent forms and statements about
benefits (e.g., absence of benefits or existence of possible
benefits) in almost all (98%; Table 1).
Table 2 presents more detailed data on the conditions
of information on potential harms (risks) and benefits
found in the sample. The most widely listed benefit to
participation in the informed consent documents related
to contributing to a better understanding of brain func-
tion or brain dysfunction (72%). Some informed consent
documents described that a participant could benefit
Table 1 TCPS general conditions of informed consent found in approved consent forms
General conditions of informed consent according to the TCPS n %
A. Individual invited to research project* 32 74%
B. Statement of research purpose, identity of designated researcher, expected duration of study, description of research
procedures*
43 100%
Statement of research purpose 43 100%
Expected duration of study 43 100%
Description of research procedures 43 100%
Screening procedures 39 91%
Identity of designated researcher 41 90%
C. Description of reasonably foreseeable harms and benefits, consequences of non-action*, ** 43 100%
Potential risks 43 100%
Potential benefits 42 98%
D. Assurance of freedom not to participate, right to withdraw, identification of continuing and meaningful opportunities to
continue to participate*
43 100%
Right to withdraw 43 100%
Freedom not to participate 39 91%
Continuing and meaningful opportunities to participate 11 26%
Consequences of non-action 36 84%
E. Conflict of interest and commercialization* 9 21%
*Categories bolded (A, B, C, D, E) indicate a general category of information required by the Canadian Tri-Council Policy Statement (TCPS).[13]
** “Consequences of non-action” designate the consequences of not being enrolled in the protocol. This aspect concerns more directly pharmacological trials or
invasive trials.[13] See Table 3 for breakdown data on risks and benefits. “Benefits” also include claims about the non-existence of benefits.
Table 2 Description of foreseeable harms and benefits in
approved consent forms*
n%
Potential benefits* 42 98%
Better understanding of brain function or dysfunction 31 72%
No personal benefit 27 63%
Future benefit to other patients 18 42%
Technical improvements to existing methods 8 19%
Clinical benefits 4 9%
Detection of incidental findings** 4 9%
Potential risks* 43 100%
Physical risks*** 40 93%
Psychological risks**** 24 56%
Unidentified risks 14 33%
No risks, minimal, risks or risk minimizing statement 39 91%
Risk-mitigating strategies 34 79%
Pregnancy-related risks 9 21%
* Categories in bold indicate a general category of information required by
the Canadian Tri-Council Policy Statement (TCPS). Other rows report how
consent forms dealt with the general conditions.
** Protocols described incidental findings as “neuro-abnormalities”.
*** See text for breakdown data of physical risks.
**** Psychological risks were almost entirely related to claustrophobia.
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Half the forms (53%) presented statements to dispel any
misunderstanding that the research proposal would pro-
vide clinical benefits, i.e., a diagnostic or therapeutic
misconception (e.g., “You should be aware that the
X-Institute for Y is not a medical setting but a research
organization. Also, you should know that the images
that will be taken do not meet the criteria for clinical
diagnostics” and “This is a research study so you will
not personally benefit, clinically or financially, by partici-
pating in this study”). Physical risks, which were identi-
fied in 93% of informed consent forms included
descriptions as follows: (1) the risks created by the pre-
sence of metal objects (implanted or not) (72%);
(2) high noise levels (67%); (3) the risks of tissue burns
(19%); (4) possible dizziness and or lightheadedness
(19%); (5) physical discomfort (16%); and (6) stress and
fatigue (16%). Risks related to sedation were described
in 5% of the protocols but this procedure is not com-
mon to all neuroimaging research protocols. Certain
categories of risks (e.g., pregnancy-related risks, psycho-
logical risks) were not addressed in all protocols. State-
ments about unidentifiable risks were included in only
33% of the consent forms.
Statements that there were “no risks” or statements
which minimized risk were present in 91% of the ana-
lyzed consent forms despite infrequent but severe risks
of injury associated with MRI and fMRI due to the mag-
netic field that can damage implanted metal devices or
pull loose metal objects. [7] Many statements were mod-
erate (i.e., “risk-minimizing statements”)b u ts o m e
clearly stated that there were no risks involved:
“The fMRI experiment might be tiring but is not
dangerous or invasive
(...) There are no risks involved in participating in
any part of the study”.
“There is no harm associated with the scanner and
the process is painless”.
“MRI scanners do not use radiation and are not
known to be dangerous in any way”.
Statements reporting strategies to mitigate risk were
presented in 79% of the informed consent documents
included. Some examples of these statements included
the following:
￿ Actions researchers do to prevent risk (49%) (e.g.,
“MRI is noisy. In order to protect your hearing, we
will provide you with ear plugs for your safety” and
“To minimize anxiety associated with a feeling of
claustrophobia experienced by some children during
the extended study period inside the magnet, your
child will be encouraged to enter the magnet for
short periods to experience the sensation before pro-
viding their final consent to participate”).
￿ Researcher responsibility in case of injury (28%)
(e.g., “If you become ill or injured as a direct result of
participating in this study, necessary medical treat-
ment will be available at no additional cost to you”).
2. Additional information that may be required by REBs
The TCPS indicates that a number of content items may
be required by REBs depending on the nature of the
study (Table 1 of TCPS document, page 2.7). [13] Many
of these items were covered in a majority of consent
forms (e.g., confidentiality in a broad sense, study com-
pensation) but others appeared only in minority of
approved consent forms (e.g., circumstances for termi-
nation of the study, explanation of the responsibilities of
subjects) (Table 3). Study compensation took various
forms: (1) reimbursement of expenses (47%); (2) com-
pensation for time and participation (42%); (3) payment
per hour or session (26%); (4) picture of subject’sb r a i n
offered as compensation (21%); (5) no compensation
offered (9%); (6) gifts offered (7%); (7) school credit
(7%); (8) and food (2%).
3. Management of incidental findings
In our sample, we encountered 13 distinct methods or
strategies used by REBs to handle incidental findings
(see Table 4). Strategies between sites varied in terms of
their specific attributes, for example, on whether or not
the subject was given the choice to be informed of pos-
sible incidental findings, and how or what medical spe-
cialists were, or were not, brought in to examine
research scans upon discovering incidental findings. We
further analyzed the within-site consistency in handling
incidental findings for the six sites where we had col-
lected four or more consent forms. We identified varia-
bility in five out of six sites we examined (Table 5); only
one site (site 2) used a single strategy consistently (strat-
egy C).
Discussion
The overall efficacy and performance of ethics review
systems have not been investigated thoroughly in spite
of their important role of protecting research subjects
and ensuring the continuity of the research enterprise.
Canada has a long history of research ethics governance
and has inspired research ethics review in other coun-
tries thus evidence on its workings may have national
and broader international relevance. [14] The results of
our analysis of approved consent forms for MRI and
fMRI research in the Canadian context provides some
perspectives on the ethics review process, a process that
has been reported as challenging for neuroscientists to
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significant variability and inconsistency in important
areas in neuroimaging research such as risk reporting
and the management of incidental findings. For exam-
ple, we found evidence of substantial between-site and
within-site variability in the strategies approved to han-
dle incidental findings. There were also significant varia-
tions in the disclosure of risks associated with MRI and
fMRI consent forms, especially with respect to psycholo-
gical risks and risks associated with dizziness,
discomfort, stress, and fatigue. We also encountered a
few forms where the risks of MRI were downplayed (e.
g., “no-risk” statements) and incidental findings were
described as a benefit.
There are important limitations to keep in mind in
this retrospective study of approved consent forms.
First, the study is based on a convenience sample and
we relied on researchers to send us their most recent
approved consent forms. This could have induced some
biases if researchers did not conform to this instruction
Table 3 Additional information that may be required by REBs for informed consent according to the TCPS*
Information that may be required by REBs n %
Statement that new information about the study will be provided* 13 30%
Identification of qualified representative to explain research 38 88%
Identification of appropriate resources outside research team for ethical issues 41 95%
Explanation of procedures of confidentiality and access to research data 43 100%
Who has access to data 35 81%
Modalities for the storage of the data 34 79%
Confidentiality in the dissemination of research 31 74%
Disclaimer of non-guarantee of confidentiality 30 70%
Explicit statements about non-guarantee of confidentiality 15 35%
Implied non-guarantee of confidentiality 28 65%
Description of the methods to protect confidentiality of data 12 28%
Description of circumstances for termination of subjects participation 18 42%
No reason needed 15 35%
Subject’s best interest 5 12%
Subject is unable or unwilling to comply with study protocol 3 7%
Description of study compensation*** 39 91%
Explanation of the ways in which results will be published 29 67%
Ways research will be published 25 58%
Subject access to published results 11 26%
* Information that may be required based on Table 1 of the TCPS (Section D, 2.6).
Categories highlighted in bold indicate a general category of information of the Canadian Tri-Council Policy Statement (TCPS). Other rows report how consent
forms dealt with the general conditions. We did not include items 5, 8 and 9 of Table 1 of the TCPS since they concern randomization and biomedical
procedures and trials.
**New information about the study conveyed to subject if likely to change subject’s decision to participate.
***See breakdown data in the text.
Table 4 Strategies proposed to handle incidental findings (IF) in approved consent forms
Strategies identified (A to M)
Attributes of strategies A B C D E F G H I J K L M
Subject has the choice to be informed of IF N Y N ? ? ? N N N N Y N N
Scans will be reviewed by a medical specialist N ? N N N Y ? ? Y Y Y N N
Subject will be directly informed of findings Y Y Y Y ? ? Y Y N Y N N N
Subject’s physician will be informed of findings Y Y Y Y Y Y ? N Y Y Y Y N
Subject has the choice for the physician to be informed Y Y Y Y Y Y ? N N N Y N N
Physician must be informed (subject has no choice) N N N N N N ? N Y Y N Y N
No mention of option to inform or not physician N N N N N N ? Y N N N N N
Subject will be invited for follow-up scan in case of IF N N Y Y N N ? N N N N N N
Total frequency of different strategies to handle IF 6242112141411 4
Y = yes (attribute is present).
N = no (attribute is not present).
? = uncertainty or ambiguity in presence of the attribute.
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Getting access directly to REB-approved files would have
been another route but this has been reported to be diffi-
cult in other studies on MRI research. [17] Second, we did
not manage to collect forms from all sites in representative
proportions and therefore our results should not be inter-
preted as an exact representation of the Canadian situa-
t i o n .T h i r d ,o u rf o c u si nt h i sp a p e ri st or e p o r t
observations on the research ethics process based on the
examination of informed consent forms. This could be cri-
ticized since research ethics, and even informed consent,
involves much more than the informed consent form
itself. The presentation of the consent form is only a por-
tion of the consent process and the verbal exchange
between the participant and the researcher introduces sev-
eral other variables that are unaccounted for in this speci-
fic study. However, a focus on this aspect of ethics review
allows us to gain insights on a deliverable of ethics review
that has perhaps been vested with the most practical and
academic energies. Finally, another limitation consists of
our focus on a typically minimal-risk research area and
the potential generalizability of our findings. On the one
hand, REBs may not consider as extensively minimal risk
research as they do with invasive and riskier research. This
would be consistent with the proportionate approach of
the TCPS which advocates adjusting the level of ethics
review scrutiny to the level of risk of a study. On the other
hand, MRI and fMRI make compelling cases to examine if
ar e l a t i v e l ys a f ea n dm i n i m a lr i s ka r e ai sd e a l tw i t ha d e -
quately or not.
Although it’se a s yt oc o n c l u d et h a tR E B sc o u l db e
faulty for any variability and inconsistency observed in
the process or final approved ethics documents, it is
worth reiterating that research ethics and ethics review
are shared responsibilities and that ethics governance
systems are comprised of distinct key stakeholders such
as researchers, REBs, funding bodies, and academic
institutions.
One possible partial explanation for the variability and
apparent inconsistency we observed could be explained
by sensitivity of REBs to local concerns. REBs were cre-
ated to respond to local concerns of patient and subject
c o m m u n i t i e sa sw e l la sl o c a la d m i n i s t r a t i o n sa n dc u l -
tures. Accordingly, reported variability could reflect the
fact that the institutional and research context varies
between sites (e.g., having access to clinicians or not in
strategies deployed to handle incidental findings). How-
ever, variability is somewhat hard to justify on this basis,
given that different strategies for incidental findings
were approved by the same institution. Further, some
variability in the reporting of risks seems hard to under-
stand on the basis of local concern, considering subject
protection and information are key goals of all REBs
and research ethics policy and that the basic risks of
MRI and fMRI do not vary in essence between sites.
Another partial explanation relates to lack of cohesion
and consensus, across Canadian researchers and REBs,
about the risks involved in MRI and fMRI studies.
[17,18] The causes of this could be manifold: lack of a
common and standard understanding of the risks related
to MRI by researchers and REBs, lack of access to
knowledge of the risks of MRI (e.g., review papers on
risks of MRI, MRI guidelines of the Food and Drug
Administration or Health Canada); inconsistent applica-
tion of commonly accepted knowledge of the risks of
MRI; lack of REB resources to review the specificities of
the risks of novel technologies; lack of consensus
between researchers and REBs on the risks of MRI that
should be reported to subjects. A previous study using a
mock review of fMRI results suggested that although
REBs tend to use similar criteria, they can arrive at radi-
cally different decisions. [19]
From a research ethics standpoint, the variability and
inconsistencies we observed are important because the
full disclosure of risks remains both legally mandatory
and ethically required in Canada. At least two Canadian
court decisions Halushka v. University of Saskatchewan
in 1965 and Weiss v. Solomon in Quebec have high-
lighted these obligations. [7,20,21] The variability we
encountered regarding some basic risks of MRI and
fMRI suggest that not all subjects receive similar infor-
mation to consent to research participation (e.g., varia-
bility in reporting physical and psychological risks). This
means that subjects may not be fully informed based on
Canadian standards and that protocols and informed
consent forms are being accepted with some lacunae.
The amount of variation found in risk disclosure of a
common research tool points to potential problems with
the ability of current research ethics governance systems
to deal with risks in novel neuroscience techniques like
fMRI. Additionally, there is now mounting evidence of
challenges plaguing ethics governance based on local
Table 5 Within site variability in handling incidental
findings in approved consent forms
Site Number of consent
forms per site
Incidental finding strategies
employed (see Table 4) per site
Site
1
8A , B , M
Site
2
5C
Site
3
4 D,E,F
Site
4
10 G, H, M
Site
7
5I , K , M
Site
9
7I , K , L , M
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t h eU S A ,t h eU K ,a n dA u s t r a l i a .[ 2 2 - 2 6 ]F o re x a m p l e ,
some studies and analyses have suggested that practical
shortcomings and variability in the process undermine
the trust that researchers place in REBs and creates dif-
ficulties for collaboration and open communication.
[5,16] REBs are also struggling to deal with demands of
the research community for both comprehensive in-
depth and expedient review. [27]
Administrative hurdles coupled with an increasingly
large burden of responsibility placed on researchers are
not reasons to take ethics short-cuts or to dismantle
research ethics as we know them. But the combination of
sub-optimal performance in dealing with ethics issues
clearly and consistently along with a significant practical
burden should make us reassess if our energies are well
served and if other ways of dealing with the requirement
of a proper assessment of ethical issues should be consid-
ered. Based on several reports about the challenges
encountered in current research ethics governance sys-
tems, the status quo option appears hard to defend in
research-intensive countries with similar ethics systems
like the US, Canada, and the UK. Several reports on
ethics governance in these countries indicate structural
problems that will not be resolved by only more of the
same practice and policy. [28] Different strategies could
be adopted to revise current research ethics governance.
In Canada, a revision process of the TCPS is taking place.
[29] However, little in the proposed revisions seems to
address the practical or administrative issues that may
make the ethics review process difficult or inconsistent.
The focus is on reshaping the policy itself, not its imple-
mentation by REBs and research institutions. [30] Addi-
tionally, we lack an evidence-based approach to making
revisions that would be commanded by both evidence
about the existence of problems and evidence about the
efficiency of proposed revisions. [5]
Conclusion
T h et i m et oe n g a g ei no p e n - m i n d e dd i s c u s s i o n sa b o u t
changes to align the priorities of ethics governance to
subject protection and information with administrative
responsiveness and accountability seems ripe. We need
additional research in this domain to provide solid evi-
dence on the lacunae of ethics review and the efficiency
of proposed solutions before implementation. Acknowl-
edging the shortcomings of our best efforts within the
current systems is a first step in preparing new direc-
tions and reflections crafted by the different stake-
holders of research ethics.
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